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Abstract
Background: Staphylococcus aureus is a major cause of nosocomial and community-acquired infections. However,
the rapid emergence of antibiotic resistance limits the choice of therapeutic options for treating infections caused
by this organism. Muralytic enzymes from bacteriophages have recently gained attention for their potential as
antibacterial agents against antibiotic-resistant gram-positive organisms. Phage K is a polyvalent virulent phage of
the Myoviridae family that is active against many Staphylococcus species.
Results: We identified a phage K gene, designated orf56, as encoding the phage tail-associated muralytic enzyme
(TAME). The gene product (ORF56) contains a C-terminal domain corresponding to cysteine, histidine-dependent
amidohydrolase/peptidase (CHAP), which demonstrated muralytic activity on a staphylococcal cell wall substrate
and was lethal to S. aureus cells. We constructed N-terminal truncated forms of ORF56 and arrived at a 16-kDa
protein (Lys16) that retained antistaphylococcal activity. We then generated a chimeric gene construct encoding
Lys16 and a staphylococcal cell wall-binding SH3b domain. This chimeric protein (P128) showed potent
antistaphylococcal activity on global clinical isolates of S. aureus including methicillin-resistant strains. In addition,
P128 was effective in decolonizing rat nares of S. aureus USA300 in an experimental model.
Conclusions: We identified a phage K gene that encodes a protein associated with the phage tail structure. The
muralytic activity of the phage K TAME was localized to the C-terminal CHAP domain. This potent
antistaphylococcal TAME was combined with an efficient Staphylococcus-specific cell-wall targeting domain SH3b,
resulting in the chimeric protein P128. This protein shows bactericidal activity against globally prevalent antibiotic
resistant clinical isolates of S. aureus and against the genus Staphylococcus in general. In vivo, P128 was efficacious
against methicillin-resistant S. aureus in a rat nasal colonization model.
Background
Peptidoglycan-degrading enzymes or murein hydrolases
have the ability to digest bacterial cell walls. Such
enzymes from bacteriophages represent a unique class
of antibacterial agents because of their ability to cleave
bacterial peptidoglycan in a species-specific or genus-
specific manner. Thus, they provide a means to selec-
tively target pathogens [1-3].
At the end of the bacteriophage infection process, pro-
geny are released from the host cell by lysis, which is
mediated by two phage-encoded gene products, endoly-
sins and holins [4]. Holins are transmembrane proteins
that create lesions in the cytoplasmic membrane
through which peptidoglycan-degrading enzymes (endo-
lysins) gain access to the peptidoglycan layer [4,5]. Bac-
teriophages encode another peptidoglycan-degrading
enzyme involved in the initial stages of infection that
facilitates phage DNA injection into the host cell. These
proteins, which are distinct from endolysins, aid in the
rapid lysis of host cells by a phenomenon referred to as
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“lysis from without” upon infection with high multiplici-
ties of phage [6]. Enzymes involved in DNA injection
are an integral component of the virion structure of
many phages [7-9].
Examples of these phage structure-associated peptido-
glycan-degrading enzymes include GP16 (phage T7),
GP5 (phage T4), GP4 (Salmonella phage P22), GP3
(Bacillus phage F29), ORF50 (Lactococcus lactis bacter-
iophage Tuc2009), protein 17 (Staphylococcus aureus
phage P68), and GP61 (S. aureus phage PhiMR11)
[8-15].
S. aureus is an important human pathogen responsible
for a wide variety of diseases and is a common cause of
nosocomial and community-acquired infections. The
emergence of antibiotic-resistant S. aureus strains
underscores the need to develop alternate novel thera-
pies [16-19]. In this context, we evaluated phage K, a
known polyvalent phage with a broad host range that
includes coagulase-positive and coagulase-negative sta-
phylococci [20,21].
We report here the identification of the phage tail-
associated muralytic enzyme (TAME) of phage K
(PCT publication no. WO2007/130655: publication
date November 15, 2007) [22] and generation of a chi-
meric protein that combines the lethal activity of
TAME with the SH3b staphylococcal cell wall-binding
domain of lysostaphin [23]. We demonstrated the effi-
cacy of this chimeric protein in vivo using a rat nasal
colonization model. Some of these findings were pre-
sented at the 2009 Madison Molecular Genetics of
Bacteria and Bacteriophage meeting at the University
of Wisconsin [24].
Methods
Bacterial strains, bacteriophages, plasmids, and growth
conditions
All bacterial strains used in this study are listed in two
tables (additional file 1, Table S1, additional file 2, Table
S2). Cell culture media were obtained from HiMedia
labs (India). Phage K was obtained from the National
Collection of Type Culture (NC07814-02) and propa-
gated on S. aureus RN4220 [25]. The methicillin-resis-
tant S. aureus (MRSA) strain B911 was used for
bactericidal activity assays, and RN4220 was used for
zymograms.Plasmid pET21a (Novagen, USA) was used
for cloning and the constructs were expressed under the
control of a T7 promoter. Plasmid pRG5 (ATCC) carry-
ing full-length lysostaphin was used as a template for
amplifying the SH3b domain. All cultures were grown
in Luria Bertani (LB) broth at 37°C, 200 rpm. Ampicillin
(100 μg/ml) or isopropyl b-D-1-thiogalactopyranoside
(IPTG, 1 mM) were added to the cultures as needed. All
reagents used in this study were purchased from Sigma
(USA) unless otherwise stated.
Sequence analysis and Identification of TAME
The DNA sequence of phage K was obtained from the
National Center for Biotechnology Information (NCBI)
[GenBank: AY176327] [26]. Database searches were per-
formed using BLASTN and BLASTP [27]http://www.
ncbi.nlm.nih.gov. Domain identification and protein
family allocation was performed with the Pfam database
[28]http://pfam.sanger.ac.uk/ and the Conserved Domain
Architecture Retrieval Tool [29]http://www.ncbi.nlm.nih.
gov/Structure/lexington/lexington.cgi using the default
parameters.
Cloning of orf56 and its truncated forms
Phage K DNA was prepared as previously described
[26]. All DNA manipulations were performed according
to the methods of Sambrook and Russell [30]. Briefly,
the full-length orf56 gene was amplified from phage K
DNA by polymerase chain reaction (PCR) using a for-
ward primer containing a unique NdeI site: 5’-
CCGGAATTCCATATGCGTAGAATAAGACCTAAG-
3’ and a reverse primer incorporating an XhoI site: 5’-
CCGCCGCTCGAGTTATTTCTTATCGTAAATGAA
TTGTGC-3’. Amplification was carried out using a
Smart Cycler (BioRad, USA). The 2427-bp PCR product
was gel-purified (GenElute™ gel extraction kit, Sigma,
USA) and then digested with NdeI and XhoI. After gel
purification, the DNA sequence was ligated into the
pET21a vector. Escherichia coli DH5a cells were trans-
formed with the ligation mixture, and transformants
were selected on LB plates containing 100 μg/ml ampi-
cillin. Plasmids (clones) were isolated from the transfor-
mants, screened by NdeI/XhoI digestion, and sequenced.
The plasmid containing the full-length orf56 was desig-
nated as pGMB617. Truncated forms of orf56 were gen-
erated by PCR amplification using sets of primers for
specific regions and cloned into the pET21a vector.
Clone integrity was verified by restriction analysis and
DNA sequencing.
Construction of chimera P128
The DNA fragment encoding Lys16, excluding the stop
codon, was PCR-amplified incorporating an NdeI site in
the forward primer and XhoI site in the reverse primer.
The fragment was cloned into the pET21a vector to
generate pGDC108. The SH3b binding domain of lysos-
taphin was PCR-amplified from the plasmid pRG5 with
XhoI restriction sites in both primers: forward primer
5’-CCGCCGCTCGAGACGCCGAATACAGGTTGGA
AAACAAAC-3’ and reverse primer 5’-CCGCCG
CTCGAGTCACTTTATAGTTCCCCAAAGAAC-3’.
The 300-bp PCR product was then cloned into
pGDC108 to generate pGDC128. Transcription of the
chimeric gene Lys16-SH3b in pGDC128 was driven by
the T7 promoter.
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Protein expression and purification
The highly inducible T7 expression system of E. coli was
used for hyperexpression of the target proteins. E. coli
ER2566 (NEB Inc, MA, USA) harboring the different
constructs was grown in LB at 37°C until absorbance at
600 nm (A600) reached 0.8, as determined by spectro-
photometry (BioRad, CA, USA). Protein expression was
induced by incubation with 1 mM IPTG at 37°C for 4 h.
Cells were harvested by centrifugation at 7500 × g for 10
min, resuspended in 25 mM Tris-HCl (pH 7.5), and dis-
rupted by ultrasonication. The cell lysate soluble and
insoluble fractions were separated by centrifugation at
11000 × g for 15 min, and protein expression was ana-
lyzed by 12% polyacrylamide gel electrophoresis (PAGE).
A crude soluble fraction containing the protein of inter-
est was used for zymogram analysis and the bactericidal
activity assay. After ammonium sulphate precipitation,
soluble P128 was purified by two-step ion-exchange
chromatography.
Zymogram
Denaturing SDS-PAGE (Sodium Dodecyl Sulfate -
Polyacrylamide Gel Electrophoresis) and zymograms
were performed as previously described [31]. Briefly,
muralytic activity was detected by separating protein
samples by 12% SDS-PAGE on gels containing 0.2%
of autoclaved S. aureus RN4220 cells. After electro-
phoresis, the zymograms were washed for 30 min
with distilled water at room temperature, transferred
to a buffer containing 25 mM Tris-HCl (pH 7.5) and
0.1% Triton X-100, and incubated for 16 h at 37°C
for in situ protein renaturation. The zymograms were
rinsed with distilled water, stained with 0.1% methy-
lene blue and 0.001% KOH for 2 h at room tempera-
ture, and then destained with distilled water.
Peptidoglycan hydrolase activity was detected as a
clear zone against the dark blue background of
methylene blue.
Electron microscopy
Phage K particles were purified by CsCl density-gradient
ultracentrifugation. Immunoelectron microscopy was
performed by incubating approximately 5 × 108 phage
particles with Lys16 antibodies conjugated to 10-nm
gold particles (1:100) at room temperature overnight.
The 1-ml samples were briefly centrifuged at 16000 × g,
and the supernatant was collected and centrifuged at
16000 × g for 150 min. The resulting pellet was resus-
pended in 25 mM Tris-HCl (pH 7.5). A 20-μl aliquot of
this sample was loaded onto Formvar-coated grids
(TAAB Laboratories Equipment Ltd, UK) and dried.
The grids were stained with 1% phosphotungstic acid
and observed by transmission electron microscopy (Tec-
nai G2 Spirit).
Bactericidal activity assay
Bactericidal activity was assessed by measuring reduc-
tion in viable cells (CFU) after addition of P128 protein.
The method is a modified version of the National Com-
mittee on Clinical Laboratory Standards assay used for
determination of Minimum Bactericidal concentration
[32]. Briefly, the MRSA clinical isolate B911 was grown
in LB broth until A600 reached 1.0, and then an aliquot
was diluted in LB broth to obtain 1 × 108 cells/ml. Ali-
quots (100 μl) were transferred to 1.5-ml microfuge
tubes, treated with 100 μl crude or purified protein, and
incubated at 37°C for 60 min at 200 rpm. Unless other-
wise indicated, bactericidal activity was always per-
formed using 10 μg/ml of P128. Residual viable cells
were enumerated as colony-forming units (CFUs) by
serial dilution and plating on LB agar plates.
Turbidity reduction assay
Exponentially growing cells were harvested and resus-
pended in 25 mM Tris-HCl (pH 7.5). For gram-negative
cultures, cells were pelleted, resuspended in CHCl3-
saturated 50 mM Tris-HCl (pH 7.5), incubated for 45
min to expose the peptidoglycan layer, and then centri-
fuged at 3000 × g. The resulting pellet was resuspended
in 25 mM Tris-HCl (pH 7.5), and the concentration
was adjusted to about A600 of 0.8 for use as substrate
for the assay. Purified P128 (50 μg/ml) was added, and
A600 was determined at different time points (total
assay volume 1 ml).
In vivo efficacy of P128 in a rat nasal colonization model
Animal experiments were approved by the Institutional
Animal Ethics Committee and the Committee for the
Purpose of Control and Supervision of Experiments on
Animals (CPCSEA). Gangagen is registered with
CPCSEA (registration No. 1193/c/08/CPCSEA dated 21/
4/2008). Healthy female Wistar rats (6-7 weeks old)
were used in all experiments.
Evaluation of commensal nasal flora
The commensal nasal flora of the rats was evaluated by
nasal swabbing. Rat nares were swabbed by gentle
insertion and withdrawal of a sterile Microbrush×(Mi-
crobrush® International), which was moistened with
sterile 0.85% NaCl. The swab portions of the Micro-
brush were cut and then completely immersed in
0.85% NaCl (150 μl) in microfuge tubes. Tubes were
thoroughly vortexed, and the supernatant was diluted
as needed and plated on agar containing 5% sheep
blood. Staphylococcus colonies were identified based
on morphology, biochemical tests and also analyzed
using the HiStaph™ Identification kit (HiMedia). An S.
aureus-specific enzyme-linked immunosorbent assay
(ELISA) was used for confirmation.
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Experimental colonization of rat nares and evaluation of
P128 efficacy
MRSA USA300 was grown overnight on nutrient agar
containing 5% sheep blood. Colonies were harvested by
flooding the plate with sterile 0.85% NaCl. Cells were
pelleted by centrifugation (5800 × g, 10 min) and resus-
pended in sterile 0.85% NaCl (2 × 108-5 × 108 cells/μl)
for nasal instillation.
Rats were grouped and anaesthetized by intraperito-
neal injection of ketamine (90 mg/kg body weight) and
xylazine (9 mg/kg body weight). A 10-μl aliquot of S.
aureus cell suspension was instilled into the nares of all
animals on day 1. After 24 h, twice daily intranasal
treatments to anaesthetized rats were initiated according
to treatment group: P128 formulated as a hydrogel (50
mg/dose containing 100 μg P128), placebo gel that con-
tained phosphate buffered saline in place of the protein,
or Bactroban Nasal (30 mg/dose, 2% mupirocin oint-
ment, GlaxoSmithKline). On day 3, the rats were eutha-
nized by anesthetic overdose. The nasal tissue (except
for the skin around the nares) was removed and pro-
cessed for quantitative evaluation of colonization as
described previously [33,34]. Aliquots of the supernatant
(diluted as needed) were plated on nutrient agar con-
taining 5% sheep blood and incubated overnight at 37°
C. The S. aureus USA300 colonies were enumerated by
tentative identification of hemolytic phenotype. Repre-
sentative colonies from each USA300-positive animal
were then purified on LB agar for biochemical charac-
terization and confirmation by ELISA.
Confirmation of S. aureus by ELISA
Purified colonies were suspended in 0.05 M carbonate-
bicarbonate buffer (pH 9.6) to a cell density of about 1
× 109 cells/mL. A 200-μL aliquot of this cell suspension
was used to coat 96-well plates and incubated overnight
at 4°C. The wells were washed with Tris buffered saline
with 0.1% Tween20 (TBST) and blocked with 1% bovine
serum albumin (200 μL) in TBST for 1 h at 37°C. After
repeated washes with TBST, rabbit polyclonal anti-
RN4220 antiserum (100 μL, 1:20000) was added, and
plates were incubated for 1 h at 37°C. The wells were
washed again with TBST before adding alkaline phos-
phatase-labeled goat anti-rabbit antibody (100 μl,
1:5000). Plates were incubated for 1 h at 37°C. After
washing the wells, the substrate p-nitro phenyl phos-
phate (100 μL) was added, the plates were incubated for
40 min, and absorbance at 405 nm was determined.
Results
Identification of TAME of phage K
Our bioinformatics analysis indicated that phageK har-
bors two genes involved in host cell wall lysis. In addi-
tion to the endolysin gene in the lysis cassette encoded
by open reading frames (orfs) 30/32 [26], we found
another gene (orf56) encoding a muralytic enzyme near
the genes encoding structural tail proteins (Figure 1).
Orf56 codes for a 91.2-kDa protein of 808 amino acids
that possesses a C-terminal peptidoglycan-degrading
domain (amino acids 678-808). We assigned this domain
to the cysteine, histidine-dependent amidohydrolase/
peptidase (CHAP) family through bioinformatic analysis
(additional file 3, Figure S1) based on the reported char-
acteristics of this domain [35].
BLASTP [27] searches revealed that ORF56 is related
to the tail lysin protein ORF005 of Staphylococcus phage
G1 and ORF007 of Staphylococcus phage Twort. A sig-
nificant similarity was also found with GP98 of Listeria
phage A511 (E value: 1e-120), GP29 of Listeria phage
P100 (E value: 6e-120), putative tail lysin of Enterococcus
phage PhiEF24C (E value: 3e-100), and putative tail lysin
of Lactobacillus phage Lb338-1 (E value: 6e-53).
Protein expression and activity of ORF56 and its N-
terminal truncated forms
CHAP domain-containing proteins have been reported
to be lytic to staphylococci [36]. Incubating 100 μl crude
preparation of ORF56 with 1 × 107 cells of MRSA clini-
cal isolate B911 for 60 min reduced CFUs by 90% com-
pared with the control, demonstrating its bactericidal
activity against S. aureus (additional file 4, Figure S2).
To determine the function of ORF56, we cloned and
expressed the full-length (2427-bp) orf56 gene. This
yielded a 91-kDa protein as well as lower molecular-
weight proteins, all of which showed muralytic activity
on zymograms. This observation led us to generate trun-
cated forms of ORF56 (57, 50, 23, 19, 16, and 13 kDa)
(Figure 2a), all of which showed muralytic activity on
zymograms and bactericidal activity against live Staphylo-
coccus cells, except for the 13-kDa form, which was active
only on zymograms (data not shown). The truncated 16-
kDa ORF56, designated as Lys16 (Figure 2b), which
showed cell wall-degrading activity on zymogram (Figure
2c) and lethal activity in S. aureus cultures (Figure 2d),
was chosen for further characterization and development.
Confirmation of ORF56 as TAME
Immunogold electron microscopy was used to confirm
that ORF56 is a part of the phage structure. We purified
phage K by CsCl density gradient centrifugation and
incubated phage particles with immunogold-labeled
antibodies directed against Lys16. The gold-conjugated
Lys16 antibody bound to the phage tail structure. This
binding was confirmed to be specific (Figure 3).
Antistaphylococcal chimeric protein P128
We combined the muralytic protein Lys16 with SH3b
[23], the staphylococcal cell wall-binding domain of
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Figure 1 Phage K genome. A section of Phage K genome comprising the ORFs 29 to 67 is depicted. ORFs are indicated by colored arrows:
putative lysis module (green), structural module (orange), proteins with a putative/hypothetical function (blue) and ORF56 (black).
Figure 2 ORF56 derivatives and purity profile, zymogram, and bactericidal activity of Lys16. (a) Schematic representation of ORF56 and
its N-terminal truncated forms. (b) SDS-PAGE profile of Lys16. Lane 1: molecular weight marker (97.5-14 kDa), Lane 2: purified Lys16 (5 μg). (c)
Zymogram of purified Lys16 (5 μg) on autoclaved S aureus RN4220 cells. The muralytic activity of Lys16 is seen as a clear zone. (d) Bactericidal
activity of Lys16. Purified Lys16 (100 μg/ml) reduced MRSA B911 viable CFUs by three orders of magnitude (99.9% cells killed).
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lysostaphin, to generate the chimeric protein P128 (Fig-
ure 4). The cloned sequence was verified, and the chi-
meric construct yielded a protein of about 27 kDa. The
soluble form of P128 was produced in E. coli and puri-
fied (> 95%). This protein showed muralytic activity on
a zymogram with S. aureus cells (Figure 5a, b).
The bactericidal activity of Lys16 and P128 was com-
pared by treating cells with varying concentrations of
the protein and enumerating residual CFUs. P128
demonstrated superior antistaphylococcal activity com-
pared with Lys16. At 750 ng/ml, P128 reduced viable
cell numbers by three orders of magnitude. Lys16 did
not achieve comparable activity, even at 100-fold higher
concentration (Figure 5c).
Specificity of P128 and dose-dependent activity
Purified P128 (50 μg/mL) was tested then for activity
against Escherichia coli, Enterococcus faecalis, Sterptococ-
cus pyogenes, Staphylococcus epidermidis Klebsiella
pneumoniae, Pseudomonas aeruginosa, Staphylococcus
carnosus, Staphylococcus aureus COL, and Staphylococ-
cus aureus USA300. P128 was specific to Staphylococcus
strains and caused significant reduction in the turbidity
of the cultures, measured by optical density at 600 nm
(A600). The cultures lysed within 15 minutes of addition
of the protein. In contrast, the gram-negative cultures
tested were not affected by P128 (Figure 6a).
The bactericidal activity of P128 against Staphylococ-
cus strains was dose-dependent.
The minimum concentration of P128 required achieve
> 99.9% killing was determined by a bactericidal activity
assay with the MRSA COL strain. We found that con-
centrations ≥ 2.5 μg/mL killed > 99.9% of the cells (Fig-
ure 6b).
Activity against global panel of S. aureus strains
To further characterize P128, its antimicrobial activity
was tested on a panel of typed S. aureus strains, repre-
senting more than 3000 isolates worldwide. This panel
included several MRSA strains and the clinically signifi-
cant strains USA100, USA300, and USA400 (see addi-
tional file 1, Table S1). P128 reduced the cell numbers
Figure 4 Construction of chimera P128. Schematic representation of the phage K orf56 gene showing the CHAP domain-encoding region and
plasmid maps showing P128 construction. P128 was generated by fusing the Lys16 coding sequence that contains the muralytic CHAP domain
of orf56 with the staphylococcal cell-wall targeting SH3b domain from lysostaphin.
Figure 3 Confirmation of ORF56-Lys16 as TAME of phage K by
immunogold-electron microscopy. Phage K particles were reacted
with gold-conjugated polyclonal rabbit antibodies (10-nm
immunogold particles) directed against Lys16 and subsequently
negatively stained with phosphotungstic acid. Scale bar = 200 nm.
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of these strains by 99% to 99.99%, demonstrating its effi-
cacy against isolates of clinical significance (Figure 7).
Experimental colonization of rat nares
Before initiating MRSA colonization, we evaluated the
commensal bacterial flora of the rat nares in several
experiments. In these Wistar rats, we found Staphylococ-
cus strains including S. sciuri subsp. rodentium, S. chro-
mogenes, and S. equorum; however, S. aureus was not
detected (data not shown). Multiple experiments were
performed using a total of 50 rats to establish the rate
and the degree of colonization of MRSA USA300 on
day 3 after instillation. Overall, 47 of 50 animals (94%)
were colonized, and the median CFU recovered from
the colonized animals was 2 × 104 (additional file 5,
Table S3).
Evaluation of P128 efficacy in vivo
At the time of treatment, one death had occurred in
each of the placebo and P128 treatment groups. In the
remaining rats, P128 hydrogel was found to completely
decolonize four of nine (44.4%) animals (Table 1). Med-
ian CFU numbers recovered in the P128 hydrogel-trea-
ted group was two orders of magnitude lower than
those of the other groups. All animals in the coloniza-
tion control group and the groups treated with placebo
or mupirocin remained colonized, as demonstrated by
the large number of recoverable bacteria (Figure 8). To
our knowledge, this is the first demonstration of efficacy
against mupirocin-resistant community-associated
MRSA USA300 in a nasal colonization model.
Discussion
There has been considerable interest in phage endoly-
sins as potential therapeutic targets. These cell wall-
degrading enzymes play a role in releasing phage pro-
geny at the end of the phage replication cycle. However,
in this study we focused on enzymes capable of similar
cell wall-degrading activity. These proteins are present
as part of phage structure and are involved in the initial
phase of phage infection. Phage tail-like bacteriocins
produced by many Pseudomonas strains [37,38] kill
other Pseudomonas strains by adsorbing to them and
causing a fatal lesion in the cell envelope [39]. Both
bacteriophages and phage-tail-like bacteriocins exert
their lethal activity using a structural component. Struc-
turally associated muralytic enzymes of phages have
been identified at the base of the tail (e.g., T4 phage),
within the phage head (e.g., T7 phage), in the internal
membrane of the capsid (e.g., PRD1), or in the nucleo-
capsid (e.g., Phi6). The localization of the enzyme is
associated with the distinct mode of cell entry used by
each phage. Considering that TAMEs are part of the
infection apparatus, they have a direct role in the speci-
ficity of phage-host interaction. These proteins are con-
stantly exposed to environments encountered by the
phage, suggesting that they are inherently stable. Phage
TAMEs would therefore be generally well suited for
antibacterial therapy. The focus of our study is such a
structural protein, phage K TAME, which possesses
bactericidal properties.
In this study, we identified a gene (orf56) within the










Figure 5 SDS-PAGE profile and biological activity of P128 in zymogram and on live S. aureus cells. (a) SDS-PAGE profile of P128. Lane 1:
molecular weight marker (97.5-14 kDa), Lane 2: purified P128 (5 μg). (b) Zymogram of purified P128 (5 μg) on autoclaved S. aureus RN4220 cells.
Muralytic activity of P128 is seen as a clear zone. (c) Varying concentrations of P128 was added to log-phase cells of MRSA B911 to evaluate
biological activity on live cells. P128 was lethal at low (ng) concentrations. A 100-fold higher concentration of Lys16 was required for comparable
activity.
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genome that codes for a muralytic protein. We also car-
ried out functional analysis of the gene product, which
we designated as a TAME. The orf56 sequence is
located in the tail gene cluster of the phage genome and
shows significant sequence similarity with putative tail
lysins of other phages of gram-positive bacteria. The
catalytic region that confers bactericidal activity to
ORF56 is localized to the C-terminal CHAP domain.
We generated truncated versions of ORF56 by PCR-
amplifying specific lengths of orf56 gene followed by
cloning and expression. Zymogram analysis showed that
the truncated forms of ORF56 were active against S.
aureus peptidoglycan. Through this analysis, we
identified the 16-kDa C-terminal region as the mini-
mum portion of ORF56 required for bactericidal activity.
This 16-kDa protein (Lys16) containing the CHAP
domain was purified and found to be stable. Adding 100
μg/ml purified Lys16 to MRSA clinical isolates reduced
cell numbers by 99.9%, demonstrating its antibacterial
property (Figure 2).
Using antibodies against Lys 16, we were able to loca-
lize the protein on the phage tail structure. CHAP
domains are present in a wide variety of proteins,
including phage endolysins, bacterial autolysins, and var-
ious eukaryotic proteins. Most proteins that contain a
CHAP domain function are peptidoglycan hydrolases
Figure 6 Specificity and dose-dependent bactericidal activity of P128. (a) P128 (50 μg/ml) was tested on log phase cells of gram positive
and gram negative bacterial species by the turbidity reduction assay. P128 showed activity only against Staphylococcus species, which lysed
rapidly after addition of the protein. No activity was observed against gram-negative bacteria or the other gram-positive bacteria tested. (b) The
bactericidal effects of P128 are dose-dependent and 0.5 μg/ml was sufficient to reduce viable cell numbers by 90%. Reduction in viable cell
numbers of over three orders of magnitude was observed in the concentration range of 2.5 - 25 μg/ml.
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and are associated with amidases [35,40]. No other
known domains were identified in ORF56. Like the tail-
associated lysin Tal2009, ORF56 undergoes autoproteo-
lysis upon hyperexpression in an E. coli host [41].
Phage-encoded lytic enzymes typically have a modular
organization consisting of a catalytic domain that
degrades the peptidoglycan and a binding domain that
recognizes the cell wall of the target bacterium [42].
However, no cell wall-binding domain could be identi-
fied in ORF56. NCBI BLAST [27] and Pfam [28] data-
bases were used to compare cell wall targeting/binding
domains of various Staphylococcus spp and their phages
to select a suitable domain that could be fused to Lys16.
Our objective was to generate a chimeric protein with
high specificity of target recognition and potent antista-
phylococcal activity. To this end, we combined the mur-
alytic activity of Lys16 with the known specific bacterial
cell wall-binding SH3b domain from lysostaphin [23].
The chimeric protein P128 displayed higher activity
than Lys16 and was found to be potent against S. aureus
(Figure 4).
P128 was effective on a panel of MRSA and methicil-
lin-sensitive S. aureus clinical isolates representing more
than 3,000 isolates (Figure 7). In addition, we demon-
strated the in vivo efficacy of P128 in a rat S. aureus
nasal colonization model (Figure 8). We chose this
model because growing evidence points to nasal carriage
as the source of S. aureus infections in various clinical
and community settings [43-45]. Although topical
mupirocin is effective in clearing nasal S. aureus and
reducing the incidence of infection, mupirocin resistance
is limiting its preventative and therapeutic use [46,47].
In our study, we used USA300, which is a community-
acquired mupirocin-resistant MRSA strain of high clini-
cal significance [48]. To our knowledge, this is the first
report of USA300 use in a nasal colonization model.
P128 applied to rat nares in the form of an aqueous gel
Figure 7 Bactericidal activity of P128 on a panel of distinct clinical isolates. Thirty globally represented S aureus clinical isolates consisting
of MRSA and methicillin-sensitive S. aureus strains demonstrated sensitivity to P128 (10 μg/ml) with significant reduction in viable cell numbers.
Blue bars represent cell controls and purple bars represent P128-treated cells.
Table 1 MRSA colonization of rat nares after treatment
Group Colonization (%) CFUs recovered
Colonization control 10/10 (100) 2 × 103-1.75 × 105
Placebo hydrogel 8/9 (88.8) 1.5 × 102-7.5 × 104
P128 hydrogel 5/9 (55.5) 5 × 100-7.5 × 103
Bactroban Nasal 10/10 (100) 1.5 × 103-2.53 × 104
Figure 8 Evaluation of P128 in vivo efficacy. The median CFU
number recovered in the P128 hydrogel-treated group was two
orders of magnitude lower than that of the other groups.
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either decolonized the nares of USA300 completely or
significantly reduced cell numbers. Thus, P128 is a
novel chimeric protein with potent antistaphylococcal
activity and warrants further development for therapeu-
tic use.
Conclusions
We report the development of a novel chimeric antista-
phylococcal protein derived from phage K. The phage K
gene, designated orf56 and encoding a TAME, was iden-
tified within the morphogenetic module of the phage
genome. The 91-kDa gene product (ORF56) contained a
sequence corresponding to the CHAP domain at the C-
terminus. We cloned and expressed several N-terminal
truncated forms of the orf56 gene to arrive at the smal-
lest portion of the protein essential for antistaphylococ-
cal activity. This 16-kDa protein (Lys16) was fused with
an efficient staphylococcal cell-wall targeting domain
(SH3b) derived from the bacterial protein lysostaphin to
create the chimeric protein P128.
P128 shows specific activity against Staphylococci and
lethal effects against S. aureus isolates of clinical signifi-
cance and global representation. We tested the protein
in an experimental nasal colonization model using
MRSA USA300 and found it effective in decolonizing S.
aureus in rat nares. Taken together, our findings show
that P128 is a promising therapeutic protein candidate
against antibiotic-resistant Staphylococci.
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